Investor Resources Home

Webcast ImageWebcast - Replay
Heron Therapeutics Inc at 35th Annual J.P. Morgan Healthcare Conference
01/12/17 at 9:30 a.m. PT
At Heron, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents.
HRTX (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$12.90
Change (%)0.00 (0.00%)
Volume868,352
Data as of 01/13/17 4:00 p.m. ET
Refresh quote

Corporate Presentation

DateTitle
01/05/17
Download Documentation Company Update (January)

Recent News

More >>
DateTitle 
01/12/17Heron Announces Submission of CINVANTI™ NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)Printer Friendly Version
01/05/17Heron Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
01/04/17Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in AbdominoplastyPrinter Friendly Version
01/04/17Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical StudiesPrinter Friendly Version

Upcoming Events

More >>

There are currently no events scheduled.

Data provided by NASDAQ. Minimum 15 minutes delayed.